Building a Follow-On Business: $3 Billion Reasons to Love Biosimilars
This article was originally published in RPM Report
Executive Summary
One Wall Street analyst thinks biosimilars could represent a $3 billion dollar business line for Amgen in less than a decade. Is that attractive enough to pursue a follow-on strategy for innovator companies? The answer is an unqualified yes.
You may also be interested in...
Biosimilars Naming Conventions On FTC Agenda – In More Ways Than One
An planned Federal Trade Commission hearing on biosimilar competition will include discussion of the debate over the right approach to non-proprietary names. But FTC may be reopening another naming debate by referring to the hearing topic as “follow-on biologics.”
Words Of Wisdom For Biosimilar Developers
FDA has learned a lot from its biosimilar meetings and sponsor discussions so far – including the areas sponsors struggle with and how others might improve their understanding going forward.
BIO Responds On Naming
The Biotechnology Industry Organization submitted the following letter in response to this article, after it was published on-line in July.